LOS ANGELES--(BUSINESS WIRE)--Kite Pharma Inc. (Kite), a biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development and commercialization of novel engineered peripheral blood autologous T cell therapeutics (eACT) for the treatment of multiple cancer indications. The collaboration with the Surgery Branch at NCI, led by Steven A. Rosenberg M.D., Ph.D., provides Kite with exclusive access to the current and future clinical product pipeline of autologous peripheral blood T cells, engineered with the NCI’s proprietary tumor-specific T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), directed to multiple hematological and solid tumor types.
